Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Management should come out and explain why and what’s next!

<< Previous

Bullboard Posts

Next >>

Comment by polygraph46on Apr 16, 2020 2:23pm

115 Views

Post# 30917801

RE:Management should come out and explain why and what’s next!

ET........for sure, what in blazes ( recent covig-19 nova scotia term thank you) is going on with

management? Bassa left Kaly in Oct 2017. Farrell takes

over as CEO. Then, fast forward to March 2020, Bassa would replace Farrell as new CEO of Kaly

before the Stero deal went south. Looks like Bassa bailed out even with the deal favouring

his. Kaly's main bread and butter has been the highly touted GVHD success and with Farells long

long experience in this field, the expectation is that this should fly. But, it hasn't...and that's what's

puzzling......pg46

<< Previous

Bullboard Posts

Next >>

@ the Bell: TSX advances to start off Christmas trading week